ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway

Cancer Research

Volumn 65, Issue 24, 2005, Pages 11314-11325

  Suzuki, Chie ^a   Daigo, Yataro ^a   Ishikawa, Nobuhisa ^a   Kato, Tatsuya ^a   Hayama, Satoshi ^a   Ito, Tomoo ^b   Tsuchiya, Eiju ^c   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; ANILLIN; GUANOSINE TRIPHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANLN GENE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CELL MOTILITY; CELL STRAIN 3T3; CELL STRAIN COS7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA SYNTHESIS; DROSOPHILA; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STRESS FIBER; TISSUE MICROARRAY; TRANSACTIVATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTINS; ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CONTRACTILE PROTEINS; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 29244464335     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1507     Document Type: Article

References (45)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. Sozzi G. Molecular biology of lung cancer. Eur J Cancer 2001;37:63-73.
3. Kelly K, Crowley J, Bunn PA, Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
4. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
5. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-205.
6. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003;1:485-99.
7. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004;13: 3029-43.
8. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003;63:7038-41.
9. Ishikawa N, Daigo Y, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004;10:8363-70.
10. Kato T, Daigo Y, Hayama S, et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 2005;65:5638-46.
11. Furukawa C, Daigo Y, Ishikawa N, et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 2005;65:7102-10.
12. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176-84.
13. Oegema K, Savoian MS, Matchinson TJ, Field CM. Functional analysis of a human homologue of the Drosophila actin binding protein anillin suggests a role in cytokinesis. J Cell Biol 2000;150:539-51.
14. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:620-35.
15. Sahai E, Marshall CJ. Rho-GTPases and cancer. Nat Rev Cancer 2002;2:133-42.
16. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell 2004;116:167-79.
17. Riedly AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992;70:389-99.
18. Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROKa is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996;16:5313-27.
19. Amano A, Chihara K, Kimura K, et al. Formation of actin stress fibers and focal adhesions enhanced by rho-kinase. Science 1997;275:1308-11.
20. Klippel A, Escobedo MA, Wachowicz MS, et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 1998;18:5699-711.
21. Liang J, Slingerland JM. Multiple roles of the P13K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.
22. Chun KH, Kosmeder JW II, Sun S, et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003;95: 291-302.
23. Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003;17:590-603.
24. Sakoda H, Goto Y, Katagiri H, et al. Differing roles of Akt and serum- and glucocorticoid-regulated kinase in glucose metabolism, DNA synthesis, and oncogenic activity. J Biol Chem 2003;278:25802-7.
25. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
26. Chin SF, Daigo Y, Huang HE, et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003;56: 275-9.
27. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003;12:27-34.
28. Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005;205:388-96.
29. Obata T, Yaffe MB, Leparc GG, et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem 2000;275:36108-15.
30. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-8.
31. Danen EH, Sonneveld P, Sonneberg A, Yamada KM. Dual stimulation of Ras/mitogen-activated protein kinase and RhoA by cell adhesion to fibronectin supports growth factor-stimulated cell cycle progression. J Cell Biol 2000;151:1413-22.
32. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac and CDC42 GTPases in cell cycle progression through G1. Science 1995;269:1270-2.
33. Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-β1 mediates epithelial to mesenchymal transition through a RhoA-dependent mechanism. Mol Biol Cell 2001;12:27-36.
34. Liu AX, Rane N, Liu JP, Prendergast GC. Rhob is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol 2001;21:6906-12.
35. Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG. Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 2000;149:775-82.
36. Brega VM. Cell-cell adhesion and signaling. Curr Opin Cell Biol 2002;14:546-56.
37. Thompson PW, Randi AM, Ridley AJ. Intercellular adhesion molecule (ICAM)-1, but not ICAM-2, activates RhoA and stimulates c-fos and rhoA transcription in endothelial cells. J Immunol 2002;169:1007-13.
38. DeMali KA, Wennerberg K, Burridge K. Integrin signaling to the actin cytoskeleton. Curr Opin Cell Biol 2003;15:572-82.
39. Fort P. Small GTPases of the Rho family and cell transformation. Prog Mol Subcell Biol 1999;22:159-81.
40. Zohn IM, Cambell SL, Khosravi-Far R, Rossman KL, Der CJ. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 1999;17: 1415-38.
41. Ozes ON, Mayo LD, Gustin JA, et al. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-5.
42. Romashkova JA, Makarov SS. NF-kB is a target of AKT in anti-apoptotic PDGF signaling. Nature 1999;401: 86-90.
43. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
44. Rosell R, Danenberg KD, Alberola V, et al.; Spanish Lung Cancer Group. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10:1318-25.
45. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004;10:4215-9s.